Diagnosis and tests 5 min
Liquid biopsy: what it is and when it helps
What a liquid biopsy is, which mutations can be found in blood, when it can replace a tissue test, when it cannot, and its limitations.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 23 October 2026
A liquid biopsy is a blood test that looks for fragments of tumour DNA (circulating tumour DNA, ctDNA) or tumour cells. Drawing blood is simpler and safer than a tissue biopsy.
When it helps
- Finding mutations when tissue is missing or scarce, for example in lung cancer, to choose a targeted drug.
- Choosing therapy at progression: new mutations that made a drug stop working can be detected.
- Monitoring in some patients: ctDNA dynamics may show response to treatment, but in standard practice this is still used in a limited way.
Limitations
- Not every tumour sheds DNA into blood: a negative result does not exclude a mutation.
- The method does not replace pathology for diagnosis.
- The result must be interpreted together with CT and the clinical picture, ideally by an oncologist familiar with molecular diagnostics.
How to read the result
- A mutation is found. It is a reason to discuss a targeted drug, but the decision is made together with tumour type, stage and other tests. Not every mutation found has therapeutic significance.
- No mutation found. This does not mean it is absent: in some tumours little DNA enters the blood. If suspicion remains, tissue is tested.
- An unexpected finding. Sometimes changes unrelated to the tumour are found in blood (for example in clonal haematopoiesis), so the result is interpreted by the oncologist, not by the laboratory alone.
- Timing and laboratories. Panels and sensitivity differ, and results from different laboratories are not directly comparable.
What exactly is sought in blood
Tumour cells shed fragments of their DNA into the blood (circulating tumour DNA, ctDNA). The laboratory isolates them and searches for mutations that may be targets for targeted drugs. The method is non-invasive: a blood draw is needed, not a puncture of the tumour.
It is not screening and not a way to make a diagnosis from scratch. Liquid biopsy works in patients whose diagnosis is already confirmed and helps choose or review treatment.
When it is really useful
- When tissue cannot or should not be taken: the tumour is hard to reach or the condition is serious.
- When there is little material or the tissue test failed.
- At progression on targeted therapy: a resistance mutation can be found and the next drug chosen (classic example: T790M in EGFR-positive lung cancer).
- For monitoring: in some situations the change in ctDNA helps to follow response, although this is not yet standard everywhere. Do not expect a blood test to replace biopsy in all cases.
Limitations of the method
- Sensitivity depends on the tumour. Some tumours shed little DNA, for example brain tumours, and then nothing is found in blood.
- A negative result does not exclude a mutation; if in doubt, tissue testing is needed.
- Different panels and laboratories give non-comparable results, and interpretation needs experience.
- Cost. The method may be expensive, and its benefit depends on whether the result will change the doctor’s decision. Before ordering, ask the oncologist what exact question it answers.
Which tumours the method is best developed for
Liquid biopsy has been best studied in lung cancer (EGFR, ALK, KRAS, resistance mutations), colorectal, breast (ESR1, PIK3CA), prostate (BRCA, ATM) and some others. For these tumours there are recognised indications in guidelines. For brain and some other tumours sensitivity is lower.
The method is also used to monitor residual disease after surgery: these results are still studied in trials and used selectively, not yet as a routine standard everywhere.
How to choose a laboratory and what to ask
- Which panel is used and how many genes it covers.
- Sensitivity and detection limit: at what level of mutant DNA fraction the test is reliable.
- Whether the laboratory is validated and whether the oncologist has experience interpreting it.
- Timing and cost.
- What will be done with the result: drug selection, trial participation or just information. Cheap “screening” blood tests without a clinical purpose do not replace examination and can give a false alarm or false reassurance. Discuss the test with the oncologist before ordering.
What to ask your doctor
- Do I need a liquid biopsy or is a tissue test enough?
- What do we do if the result is negative?
- Which laboratory and which panel are suitable?
If you are not sure which molecular tests you really need, I can go through it with you at a consultation.
Sources
- Circulating tumor DNA (NCI Dictionary of Cancer Terms) — National Cancer Institute
Watch me explain this on video
Short videos on my Instagram (in Russian)
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
